Key points are not available for this paper at this time.
Astroglia are well known for their role in propagating secondary injury following brain trauma. Modulation of this injury cascade, including inflammation, is essential to repair and recovery. Mesenchymal stromal cells (MSCs) have been demonstrated as trophic mediators in several models of secondary CNS injury, however, there has been varied success with the use of direct implantation due to a failure to persist at the injury site. To achieve sustained therapeutic benefit, we have encapsulated MSCs in alginate microspheres and evaluated the ability of these encapsulated MSCs to attenuate neuro-inflammation. In this study, astroglial cultures were administered lipopolysaccharide (LPS) to induce inflammation and immediately co-cultured with encapsulated or monolayer human MSCs. Cultures were assayed for the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-Formula: see text produced by astroglia, MSC-produced prostaglandin E 2 , and expression of neurotrophin-associated genes. We found that encapsulated MSCs significantly reduced TNF-Formula: see text produced by LPS-stimulated astrocytes more effectively than monolayer MSCs, and this enhanced benefit commences earlier than that of monolayer MSCs. Furthermore, in support of previous findings, encapsulated MSCs constitutively produced high levels of PGE 2 , while monolayer MSCs required the presence of inflammatory stimuli to induce PGE 2 production. The early, constitutive presence of PGE 2 significantly reduced astrocyte-produced TNF-Formula: see text, while delayed administration had no effect. Finally, MSC-produced PGE 2 was not only capable of modulating inflammation, but appeared to have an additional role in stimulating astrocyte neurotrophin production. Overall, these results support the enhanced benefit of encapsulated MSC treatment, both in modulating the inflammatory response and providing neuroprotection.
Hunter et al. (Thu,) studied this question.